Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Glioma 12Glioblastoma 6Insulinoma 4Hypoglycemia 4Congenital Hyperinsulinism 4Brain Neoplasms 4Neuroendocrine Tumors 3Neuroblastoma 3Hyperinsulinism 3Recurrence 2Pheochromocytoma 2Parkinson Disease 2Oligodendroglioma 2Gliosarcoma 2Ependymoma 2Carcinoid Tumor 2Astrocytoma 2Thyroid cancer, medullary 1Sarcoma 1Parkinsonian Disorders 1Parathyroid Neoplasms 1Paraganglioma 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Endocrine Neoplasia 1Lewy Body Disease 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hypercalcemia 1

Interventions

Cinacalcet 3parathyroid hormone-related peptide (1-36) 2Bupivacaine 2gallium Ga 68 dotatate 1fluorodopa F 18 1etelcalcetide hydrochloride 1Saline Solution 1Parathyroid Hormone-Related Protein 1Parathyroid Hormone 1Dexmedetomidine 1Conscious Sedation 1Calcitriol 1Anesthesia, General 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyperparathyroidism × fluorodopa F 18 × Clear all
NCT00001277 2022-06-07

Studies of Elevated Parathyroid Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
1,553 enrolled 8 charts
EndocrineHead & Neck

Hypercalcemia, Hyperparathyroidism, Hypoglycemia, Multiple Endocrine Neoplasia, Parathyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡